In vitro activity of sparfloxacin.

The bactericidal activity of sparfloxacin.

In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.

In vitro activity of sparfloxacin compared with those of five other quinolones.

In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.

In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.

In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.

In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.

In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent.

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Antibacterial activity of sparfloxacin against experimental renal infections in mice.

In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.

In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells.

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.

Sparfloxacin-associated corneal epithelial toxicity.

Sparfloxacin and other new fluoroquinolones.

In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.

Suggest Documents

The bactericidal activity of sparfloxacin.

In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.

In vitro activity of sparfloxacin compared with those of five other quinolones.

In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.

In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.

In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.

In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.

In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent.

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

Antibacterial activity of sparfloxacin against experimental renal infections in mice.

In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.

In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells.

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.

Sparfloxacin-associated corneal epithelial toxicity.

Sparfloxacin and other new fluoroquinolones.

In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.

In vitro activity of sparfloxacin.

Recommend Documents

Follow Us